Cargando…
miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line
Background: Hepatocellular carcinoma (HCC) is the second most common malignancy with increasing cancer deaths worldwide. HCC is mainly diagnosed at its advanced stage, and treatment with FDA-approved sorafenib, the multikinase inhibitor drug, is advised. Acquired resistance against sorafenib develop...
Autores principales: | Kaur, Ramanpreet, Kanthaje, Shruthi, Taneja, Sunil, Dhiman, Radha K., Chakraborti, Anuradha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407556/ https://www.ncbi.nlm.nih.gov/pubmed/36011286 http://dx.doi.org/10.3390/genes13081375 |
Ejemplares similares
-
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
por: Makol, Ankita, et al.
Publicado: (2020) -
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
por: Taha, Amna Mohamed, et al.
Publicado: (2022) -
Glucose and glutamine availability regulate HepG2 transcriptional responses to low oxygen
por: Lai, Alvina G., et al.
Publicado: (2018) -
Effect of Combined Sorafenib/Cisplatinum Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro
por: Wang, Yaoting, et al.
Publicado: (2020) -
Crambescin C1 Exerts a Cytoprotective Effect on HepG2 Cells through Metallothionein Induction
por: Roel, María, et al.
Publicado: (2015)